vorinostat has been researched along with Carcinoma, Squamous Cell of Head and Neck in 6 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat was administered at the assigned dosage level (100-400 mg, three times weekly) in a standard 3 + 3 dose escalation design." | 2.90 | A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. ( Agrawal, A; Baiocchi, R; Blakaj, D; Carrau, R; Diavolitsis, V; Grecula, J; Kang, S; Kumar, B; Kumar, P; Old, MO; Ozer, E; Palettas, M; Pan, Q; Rocco, J; Savvides, P; Teknos, TN; Wei, L, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, C | 3 |
| Wu, QV | 4 |
| Voutsinas, J | 4 |
| Houlton, JJ | 3 |
| Barber, B | 3 |
| Futran, N | 3 |
| Laramore, GE | 3 |
| Liao, JJ | 3 |
| Parvathaneni, U | 3 |
| Martins, RG | 3 |
| Fromm, JR | 4 |
| Rodriguez, CP | 4 |
| Akhlaq, R | 1 |
| Khan, T | 1 |
| Ahmed, T | 1 |
| Musharraf, SG | 1 |
| Ali, A | 1 |
| Jiang, X | 1 |
| Pillarisetty, VG | 1 |
| Lee, SM | 1 |
| Santana-Davila, R | 1 |
| Goulart, B | 1 |
| Baik, CS | 1 |
| Chow, LQM | 1 |
| Eaton, K | 1 |
| Martins, R | 1 |
| Tanaka, N | 1 |
| Patel, AA | 1 |
| Tang, L | 1 |
| Silver, NL | 1 |
| Lindemann, A | 1 |
| Takahashi, H | 1 |
| Jaksik, R | 1 |
| Rao, X | 1 |
| Kalu, NN | 1 |
| Chen, TC | 1 |
| Wang, J | 2 |
| Frederick, MJ | 1 |
| Johnson, F | 1 |
| Gleber-Netto, FO | 1 |
| Fu, S | 1 |
| Kimmel, M | 1 |
| Hittelman, WN | 1 |
| Pickering, CR | 1 |
| Myers, JN | 1 |
| Osman, AA | 1 |
| Teknos, TN | 1 |
| Grecula, J | 1 |
| Agrawal, A | 1 |
| Old, MO | 1 |
| Ozer, E | 1 |
| Carrau, R | 1 |
| Kang, S | 1 |
| Rocco, J | 1 |
| Blakaj, D | 1 |
| Diavolitsis, V | 1 |
| Kumar, B | 1 |
| Kumar, P | 1 |
| Pan, Q | 1 |
| Palettas, M | 1 |
| Wei, L | 1 |
| Baiocchi, R | 1 |
| Savvides, P | 1 |
| Citro, S | 1 |
| Bellini, A | 1 |
| Miccolo, C | 1 |
| Ghiani, L | 1 |
| Carey, TE | 1 |
| Chiocca, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies[NCT02538510] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2015-10-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Kaplan Meier methods will be used to estimate progression free survival. (NCT02538510)
Timeframe: Up to 2 years
| Intervention | Months (Mean) |
|---|---|
| Head and Neck Squamous Cell Carcinoma | 12.6 |
| Salivary Gland Carcinoma | 14.0 |
Toxicities will be summarized as the number and percentage of patients with each type of toxicity, per Criteria for Adverse Events version 4.0 (NCT02538510)
Timeframe: Up to 30 days after the completion of study treatment
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | ALT increase | Anorexia | Arthiritis | AST increase | Cough | Increased Creatinine | Dermatitis | Diarrhea | Fever with leukocytosis | Fatigue | Hyponatremia | Hypothyroidism | Colitis and Ileitis | Malaise | Nausea | Nephritis | Pneumonitis | Neuritis | Tracheitis/Epiglottitis | Vomiting | |
| Head and Neck Squamous Cell Carcinoma | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Salivary Gland Carcinoma | 1 | 1 | 1 | 1 | 1 | 0 | 5 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 2 |
Radiologic assessments of measurable disease will be performed using radiographic imaging. RECIST 1.1 and immune response criteria will be used to assess response to therapy. Responses will be summarized as frequencies and percentages. (NCT02538510)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| partial response | stable disease | progressive disease | |
| Head and Neck Squamous Cell | 8 | 8 | 5 |
| Salivary Gland Carcinoma | 4 | 13 | 6 |
3 trials available for vorinostat and Carcinoma, Squamous Cell of Head and Neck
3 other studies available for vorinostat and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
PX-12 synergistically enhances the therapeutic efficacy of vorinostat under hypoxic tumor microenvironment in oral squamous cell carcinoma in vitro.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Disulfides; Head and Neck Neoplasms; Histone Deacetylase | 2023 |
Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferat | 2017 |
Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Gefitinib; Histone Deacetylase Inhib | 2019 |